Q4 2018 Investor Presentation
Big Data Analysis Drives Insights for
Treatment of Central Sleep Apnea
Patients with treatment-emergent central sleep apnea (CSA)
are two times more likely to terminate therapy
•
Opportunity to rethink conventional therapeutic options
• Minimize risk of therapy termination through early diagnosis
•
Regularly monitor patients to support adherence to treatment
HAH
CHEST
Journal
100
50
Analysis of ~200k CSA patients
22% increase in adherence
CMS adherence on CPAP
prior to switching
62.7%
CMS adherence
after switching to ASV
76.6%
•
Switching from therapy
CPAP to ASV improved
relative adherence by
22%
⚫ Patients who switched
from CPAP to ASV had
fewer apneas and
hyponeas during sleep
© 2018 ResMed | Q4 2018 Investor Presentation | 19
ResMedView entire presentation